ePrints

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

Lookup NU author(s): Julian Leathart, Professor Ann DalyORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Background and Objective: A large interindividual variability exists in the plasma concentrations of repaglinide. Our aim was to investigate possible associations between the pharmacokinetics of repaglinide and single nucleotide polymorphisms (SNPs) in the genes encoding for the drug transporters organic anion transporting polypeptide 1B1 (OATP1B1) (SLCO1B1) and P-glycoprotein (MDR1, ABCB1) and the drug-metabolizing enzymes cytochrome P450 (CY-P) 2C8 and CYP3A5. Methods: A total of 56 healthy volunteers ingested a single 0.25-mg dose of repaglinide. Plasma repaglinide and blood glucose concentrations were measured for up to 7 hours. All subjects were genotyped for the -11187G > A and 521T > C SNPs in SLCO1B1 and the 3435C > T and 2677G > T/A SNPs in ABCB1, as well as for the CYP2C8*3 (416G > A, 1196A > G), CYP2C8*4 (792C > G), and CYP3A5*3 (6986A > G) alleles. Results: The area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] and peak concentration in plasma (C-a.) of repaglinide varied 16.9-fold and 10.7-fold, respectively, between individual subjects. Multiple regression analyses indicated that the SLCO1B1 521T > C SNP and the CYP2C8*3 allele were independent predictors of the AUC(0-infinity) and C-max of repaglinide (adjusted multiple R-2 = 45% and 36%, respectively). In subjects with the SLCO1B1 521CC genotype, the AUC(0-infinity) of repaglinide was 107% and 188% higher, respectively, than in subjects with the SLCO1B1 521TC or 521TT (reference) genotype (P < .0001). In subjects with the CYP2C8*1/*3 genotype, the AUC(0-infinity) and C-max of repaglinide were 48% and 44% lower, respectively, than in those with the CYP2C8*1/*1 genotype (P < .05). The pharmacokinetics of repaglinide was not associated with the studied ABCB1 SNPs or the CYP3A5*3 allele. The elimination half-life of repaglinide was not associated with any SNP. Only the SLCO1B1 -11187GA genotype was significantly associated with an enhanced effect of repaglinide on blood glucose. Conclusions. Genetic polymorphism in SLCO1B1 is a major determinant of interindividual variability in the pharmacokinetics of repaglinide. The effect of SLCO1B1 polymorphism on the pharmacokinetics of repaglinide may be clinically important.

Publication metadata

Author(s): Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ

Publication type: Article

Publication status: Published

Journal: Clinical Pharmacology and Therapeutics

Year: 2005

Volume: 77

Issue: 6

Pages: 468-478

ISSN (print): 0009-9236

ISSN (electronic): 1532-6535

Publisher: Nature Publishing Group

URL: http://dx.doi.org/10.1016/j.cplt.2005.01.018

DOI: 10.1016/j.cplt.2005.01.018

Altmetrics

Share